Stockscreener 앱 받기
4.45
1.14%
0.05
시간 외 거래:
4.38
-0.07
-1.57%
전일 마감가:
$4.40
열려 있는:
$4.1708
하루 거래량:
7,282
Relative Volume:
0.03
시가총액:
$8.94M
수익:
-
순이익/손실:
$-17.10M
주가수익비율:
-0.0188
EPS:
-236.7281
순현금흐름:
$-15.92M
1주 성능:
+3.97%
1개월 성능:
-8.06%
6개월 성능:
-38.32%
1년 성능:
-33.58%
1일 변동 폭
$4.1708
$4.47
1주일 범위
$3.99
$4.47
52주 변동 폭
$3.25
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
명칭
Quoin Pharmaceuticals Ltd Adr
전화
97299741444
주소
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
4.45 | 8.62M | 0 | -17.10M | -15.92M | -236.73 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Cash flow from investing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Book value per share of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Average basic shares outstanding of Quoin Pharmaceuticals. Ltd Sponsored ADR – LSX:A41BEM - TradingView
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops - Sahm
Price to earnings forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - Sahm
Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com - Investing.com India
QNRXQuoin Pharmaceuticals Ltd ADR Volatility & Greeks - Finviz
Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX) - TradingView
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - Sahm
Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market - Moomoo
Quoin Pharmaceuticals establishes Japan subsidiary for QRX003 - Investing.com
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - Sahm
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals stock rises on rare disease IND filing By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals stock rises on rare disease IND filing - Investing.com
Number of shareholders of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results - Sahm
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
Unusual VolumeStock ScreenerNews - Finviz
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - Sahm
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - ChartMill
Form 13G Quoin Pharmaceuticals For: 15 December - Investing.com
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - livemint.com
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome - ChartMill
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome - ChartMill
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
QNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals Ltd Adr (QNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):